JOSD2

Across TCGA pan-cancer cohorts, JOSD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated JOSD2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher JOSD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JOSD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where JOSD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.861	0.131	.001	18	view →
UCEC	DFS	Median	All	0.760	1.000	.002	16	view →
LUAD	DFS	Quartile	All	0.630	1.000	.029	5	view →
HNSC	OS	Tertile	III,IV	0.592	0.821	.016	4	view →
PDAC	OS	Median	IV	0.222	0.916	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

JOSD2–CCRCC (DFS)

Open the CCRCC breakdown →